Sign in
Not yet taking people in United StatesNo phase

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS)

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
40 people, planned
Starts
1 Dec 2026
Expected to end
1 Jan 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • active nVNS
  • Sham
Record updated
18 November 2026

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • To be eligible, participants must meet all of the following criteria:; Adults aged 18 through 50 years, inclusive, at the time of consent; Able to understand and provide written informed consent in English; Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries; Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log; Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device; Regular sleep opportunity of at least 6 hours per 24-hour period; Cohort A (symptomatic) - additional inclusion criteria:; Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1; MADRS total score ≥ 20 at screening and confirmed at Visit 1; Meets DSM-5-TR criteria for insomnia disorder on structured clinical interview; If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3; Cohort B (healthy reference) - additional inclusion criteria:; ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1; No current psychiatric disorder or sleep disorder as established by structured diagnostic interview; No psychotropic medication use within the prior 30 days

Who cannot take part

  • Participants meeting any of the following criteria are not eligible:; Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation; Travel across more than two time zones within the 14 days before Visit 1, or planned during participation; Any contraindication to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, clinically significant carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site; Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site; Known or suspected pregnancy, or breastfeeding. Participants of childbearing potential will undergo urine pregnancy testing at screening; Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause; Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder; Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures; Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder; Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care; Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months; Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1; Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Insomnia or major depressive diorder or mirnas

Where in United States

  • University of Alabama at Birmingham (UAB)Birmingham, United StatesContact: Samantha WhiteNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.

Read full original descriptionShow less

The main questions it aims to answer are:

1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline? 2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms? 3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?

This study lasts about 7 weeks.

Participants will be asked to do the following:

Visit 1/ Baseline (in person):

* Participants will answer questions about their health, mood, and sleep; * have their blood pressure and pulse taken; * give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests; * be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.

This visit will last about 2 hours.

Weeks 1-6 (at home):

* Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes; * Participants will also need to wear the wrist device day and night; * Participants will fill out a short sleep diary each morning.

Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):

* Participants will repeat the questionnaires and interviews from Visit 1; * have their blood pressure and pulse taken; * give another blood sample of about 20 mL; * have the data from their wrist device downloaded. * At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.

This visit will last about 1.5 - 2 hours.

The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

The 2 groups in the trial

  • Sham Run-In (Weeks 1-2)Sham treatment, for comparison

    Inactive sham stimulation, twice daily. Each participant receives first.

    Treatment: Sham

  • Active stimulation (Weeks 3-6)Existing treatment, for comparison

    Blinded active cervical nVNS, twice daily. Each participant receives second.

    Treatment: active nVNS

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07945015, who can take part
Record updated
18 November 2026